Lisanti Capital Growth LLC Takes $1.31 Million Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Lisanti Capital Growth LLC purchased a new position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 39,845 shares of the company's stock, valued at approximately $1,311,000. Lisanti Capital Growth LLC owned approximately 0.10% of Tarsus Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Quest Partners LLC purchased a new stake in Tarsus Pharmaceuticals in the 2nd quarter worth $61,000. Canada Pension Plan Investment Board purchased a new position in shares of Tarsus Pharmaceuticals during the second quarter valued at about $114,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Tarsus Pharmaceuticals by 33.4% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company's stock valued at $166,000 after purchasing an additional 1,530 shares in the last quarter. Bleakley Financial Group LLC purchased a new position in shares of Tarsus Pharmaceuticals during the first quarter valued at about $223,000. Finally, SG Americas Securities LLC grew its position in shares of Tarsus Pharmaceuticals by 87.5% during the third quarter. SG Americas Securities LLC now owns 7,242 shares of the company's stock valued at $238,000 after purchasing an additional 3,379 shares in the last quarter. Hedge funds and other institutional investors own 90.01% of the company's stock.

Tarsus Pharmaceuticals Trading Down 0.7 %

Shares of NASDAQ:TARS traded down $0.34 during trading on Monday, reaching $49.08. The company's stock had a trading volume of 530,856 shares, compared to its average volume of 724,225. The company has a current ratio of 7.03, a quick ratio of 6.99 and a debt-to-equity ratio of 0.28. Tarsus Pharmaceuticals, Inc. has a 12 month low of $15.60 and a 12 month high of $51.59. The firm's 50 day simple moving average is $35.95 and its two-hundred day simple moving average is $32.00. The stock has a market capitalization of $1.87 billion, a PE ratio of -11.03 and a beta of 1.00.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.88) EPS for the quarter, beating analysts' consensus estimates of ($0.98) by $0.10. The firm had revenue of $40.81 million during the quarter, compared to the consensus estimate of $31.30 million. Tarsus Pharmaceuticals had a negative net margin of 180.00% and a negative return on equity of 63.99%. During the same quarter last year, the firm earned ($1.17) EPS. On average, research analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.71 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on TARS shares. William Blair upgraded Tarsus Pharmaceuticals to a "strong-buy" rating in a research report on Friday, August 30th. Oppenheimer restated an "outperform" rating and set a $63.00 price objective (up previously from $61.00) on shares of Tarsus Pharmaceuticals in a research report on Friday, August 9th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Tarsus Pharmaceuticals has an average rating of "Buy" and a consensus target price of $51.60.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.